Navigation Links
Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
Date:5/16/2008

ny is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. For more information please visit the company's website at http://www.pharmacopeia.com.

Investor Contacts:

Amy P. Sharpless

Pharmacopeia, Inc.

609-452-3643

ir_pr@pcop.com

Carney Noensie

Burns McClellan

212-365-0983

cnoensie@burnsmc.com

Media Contact:

Glenn Silver

Chamberlain Healthcare Public

Relations

212-389-9158

gsilver@chamberlainpr.com

This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, goal, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward- looking statements include, but are not limited to, statements about the results of Pharmacopeia's Phase 2a clinical study of PS433540, a product candidate from its DARA program, Pharmacopeia's plans to develop PS433540, Pharmacopeia's other Phase 2 and Phase 1 clinical studies with respect to PS433540, including timing and expected outcomes of such studies, Pharmaco
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
3. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
4. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
7. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
10. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
11. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 3, 2015  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: ... on its expertise in opioid antagonists, announced today ... treating opioid overdose with intranasal naloxone, has commenced ... (NDA) to the United States Food and Drug ... naloxone, a drug intended to treat opioid overdose. ...
(Date:6/3/2015)...  The International Confederation of Midwives (ICM) has provided ... a standard for midwives trained to ICM,s competency standards.  ... consultation with ICM experts. Direct Relief will provide the ... As many as one in 30 women ... childbirth.  Skilled birth attendants such as midwives offer the ...
(Date:6/3/2015)... 2015 According to a ... Vascular Devices Market (Embolic Protection, Chronic Total Occlusion, ... IVC Filters, Stents, Balloons and Accessories) - Forecasts ... and Peripheral Vascular Devices Market is expected to ... CAGR of 7.4% from 2014 to 2019. ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 2Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 3A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 2A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 3A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 4The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 2The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 3The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 4
... Dec. 29, 2011 BioDelivery Sciences International, Inc. (Nasdaq: ... announcement by the U.S. Food and Drug Administration (FDA) ... transmucosal fentanyl products has been approved.  The program, which ... Fentanyl (TIRF) REMS Access Program, was designed to ensure ...
... ESRX ) announced that it will present at ... 2012 at 9:00 a.m. PST (12:00 p.m. EST) at the ... The presentation will also be broadcast via the Internet and ... Scripts web site at http://www.express-scripts.co m .  RealPlayer ...
Cached Medicine Technology:ONSOLIS to Benefit from Approval of Class-Wide REMS for All Transmucosal Fentanyl Products 2ONSOLIS to Benefit from Approval of Class-Wide REMS for All Transmucosal Fentanyl Products 3ONSOLIS to Benefit from Approval of Class-Wide REMS for All Transmucosal Fentanyl Products 4
(Date:6/3/2015)... (PRWEB) June 03, 2015 A ... additional precautions on product labels underscores the importance ... according to the American Society for Dermatologic Surgery ... include new warnings about the risks for serious ... vessels. While product labels already include information about ...
(Date:6/3/2015)... Loma Linda University Health and Adventist ... Gorgonio Memorial Hospital (SGMH). The SGMH board voted unanimously ... , “Loma Linda University Health has been serving the ... executive officer, Loma Linda University Medical Center. “We are ... to this community.” , Under the proposed affiliation, ...
(Date:6/3/2015)... June 03, 2015 Johnson & Johnson ... $7.8 million to resolve a Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ... the company allegedly used to market the antipsychotic drug. ... indicate that the Arkansas Attorney General moved to dismiss ... accord. The Risperdal settlement amounts to just a fraction ...
(Date:6/3/2015)... DC (PRWEB) June 03, 2015 The ... to announce that Maria C. Savoia, M.D., Dean of Medical ... of Medicine, will become Chair on July 1. ... Chair of the National Resident Matching Program,” said Dr. Savoia. ... reliable process for matching medical students with training programs, and ...
(Date:6/3/2015)... On the heels of a report predicting ... 2020 ( click here to review news coverage about ... Baltimore has the talent to become a world-leading center ... and other biological data are collected and analyzed to help ... all the elements of a perfect storm for bioinformatics leadership,” ...
Breaking Medicine News(10 mins):Health News:ASDSA Supports FDA Fillers Directive 2Health News:ASDSA Supports FDA Fillers Directive 3Health News:ASDSA Supports FDA Fillers Directive 4Health News:Loma Linda University Health and Adventist Health Enter into Exclusive Affiliation Negotiations with San Gorgonio Memorial Hospital 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 2Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 3Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 4Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3
... stage III colon cancer treated with 5-FU-based chemotherapy after ... improved overall survival with no change in time to ... patients with stage II colon cancer treated after 1995 ... to death compared to those patients treated prior to ...
... ... Days of Intentions to mark the mid-point of 2010. , ... Los Angeles, CA (PRWEB) June 3, 2010 -- This week, Intent.com launches ... Days of Intentions is a challenge to the internet community to commit to posting one new ...
... Davis public health researchers have found that children, who ... choices, are the targets of a new medium used ... an entertaining blend of interactive animation, video content and ... online messages that primarily promote corporate branding and products. ...
... high school, study finds , THURSDAY, June 3 (HealthDay News) ... the two years following high school are less likely to ... , The finding builds on past research that had demonstrated ... and alcohol abuse. , "I,m not saying that we should ...
... but others say it,s not always that simple, , THURSDAY, ... prompts anxiety in many a parent. But having to ... story can make an already sensitive subject even more complicated. ... parents. , As assisted reproduction technology, in which someone other ...
... ... ... 2010 -- Thomas D. Meade, M.D., a nationally renowned knee specialist who has performed ... June 1, Dr. Meade will see patients at Coordinated Health facilities in Allentown, Bethlehem, ...
Cached Medicine News:Health News:Stage II and stage III colon cancer patients treated after 1995 have improved overall survival 2Health News:Intent.com Launches 30 Days of Intentions and Announces Winners of 2010 Intent Web Awards 2Health News:Online games new marketing tool for unhealthy foods 2Health News:Online games new marketing tool for unhealthy foods 3Health News:Romance May Steer Young Adults Away From Booze, Pot 2Health News:Donor-Assisted Conception Sparks Disclosure Dilemmas 2Health News:Donor-Assisted Conception Sparks Disclosure Dilemmas 3Health News:Nationally Renowned Knee Specialist Dr. Thomas Meade Joins Coordinated Health 2Health News:Nationally Renowned Knee Specialist Dr. Thomas Meade Joins Coordinated Health 3
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
Medicine Products: